Table 3.
SABA Prescriptions in the past 12 months for the SABINA III Gulf cluster cohort
|
All (N = 301) |
Primary care physicians (n = 135) | Respiratory specialists (n = 162) | |||||
|---|---|---|---|---|---|---|---|
| Mild asthma (n = 32) |
Moderate-to-severe asthma (n = 103) |
All (n = 135) |
Mild asthma (n = 13) |
Moderate-to-severe asthma (n = 149) |
All (n = 162) |
||
| Prescription of SABA monotherapy, n (%) | |||||||
| No | 287 (95.3) | 20 (62.5) | 103 (100) | 123 (91.1) | 12 (92.3) | 149 (100) | 161 (99.4) |
| Yes | 14 (4.7) | 12 (37.5) | 0 (0) | 12 (8.9) | 1 (7.7) | 0 (0) | 1 (0.6) |
| SABA canisters or inhalers prescribed in the past 12 months | |||||||
| Mean (SD) | 8.9 (12.9) | 10.2 (13.5) | NA | 10.2 (13.5) | 1.0 (NA) | NA | 1.0 (NA) |
| Median (min, max) | 2.5 (1.0, 42.0) | 3.0 (1.0, 42.0) | NA | 3.0 (1.0, 42.0) | 1.0 (1.0, 1.0) | NA | 1.0 (1.0, 1.0) |
| SABA canisters or inhalers prescribed in the past 12 months by groups, n (%) | |||||||
| 0–2 | 7 (50) | 5 (41.7) | NA | 5 (41.7) | 1 (100) | NA | 1 (100) |
| 3–5 | 3 (21.4) | 3 (25) | NA | 3 (25) | 0 (0) | NA | 0 (0) |
| 6–9 | 0 (0) | 0 (0) | NA | 0 (0) | 0 (0) | NA | 0 (0) |
| 10–12 | 1 (7.1) | 1 (8.3) | NA | 1 (8.3) | 0 (0) | NA | 0 (0) |
| ≥ 13 | 3 (21.4) | 3 (25) | NA | 3 (25) | 0 (0) | NA | 0 (0) |
| Prescription of SABA in addition to maintenance therapy/SABA add-on therapy, n (%) | |||||||
| No | 93 (30.9) | 21 (65.6) | 38 (36.9) | 59 (43.7) | 9 (69.2) | 23 (15.4) | 32 (19.8) |
| Yes | 208 (69.1) | 11 (34.4) | 65 (63.1) | 76 (56.3) | 4 (30.8) | 126 (84.6) | 130 (80.2) |
| SABA canisters or inhalers prescribed in the past 12 months | |||||||
| Mean (SD) | 8.0 (10.9) | 7.6 (4.6) | 10.6 (18.5) | 10.2 (17.2) | 7.8 (4.3) | 6.8 (4.0) | 6.8 (4.0) |
| Median (min, max) | 6.0 (1.0, 110.0) | 9.0 (2.0, 12.0) | 5.0 (1.0, 110.0) | 5.0 (1.0, 110.0) | 7.5 (4.0, 12.0) | 6.0 (1.0, 24.0) | 6.0 (1.0, 24.0) |
| SABA canisters or inhalers prescribed in the past 12 months by groups, n (%) | |||||||
| 0–2 | 39 (18.8) | 3 (27.3) | 20 (30.8) | 23 (30.3) | 0 (0) | 15 (11.9) | 15 (11.5) |
| 3–5 | 54 (26) | 2 (18.2) | 15 (23.1) | 17 (22.4) | 2 (50) | 35 (27.8) | 37 (28.5) |
| 6–9 | 61 (29.3) | 1 (9.1) | 13 (20) | 14 (18.4) | 0 (0) | 46 (36.5) | 46 (35.4) |
| 10–12 | 37 (17.8) | 5 (45.5) | 8 (12.3) | 13 (17.1) | 2 (50) | 22 (17.5) | 24 (18.5) |
| ≥ 13 | 17 (8.2) | 0 (0) | 9 (13.8) | 9 (11.8) | 0 (0) | 8 (6.3) | 8 (6.2) |
Prescriber type was not recorded for two patients each in mild asthma and moderate-to-severe asthma group
Abbreviations: max maximum, min minimum, NA not available, SABA short-acting β2-agonist, SABINA SABA use IN Asthma, SD standard deviation